Oral tranexamic acid for melasma can reduce facial pigmentation, but it is an off-label treatment with a meaningful screening step: clinicians need to assess your clotting history and other health factors before considering it. Studies report improvement, not a cure, and melasma can return after treatment ends.
What Studies Show About Oral Tranexamic Acid for Melasma
Clinical studies commonly measure change in the Melasma Area and Severity Index (MASI), a score of the affected areas and pigmentation. Results suggest oral tranexamic acid can help, often alongside sun protection or other treatments. However, study designs and treatment schedules vary, so they do not establish one best dose or predict your individual result.
In a retrospective study at a tertiary dermatology centre in Singapore, Hwee Chyen Lee, Tien Guan Steven Thng and Chee Leok Goh examined records for 561 people treated for melasma. Treatment lasted a median of four months. Of the group, 89.7% had visible improvement, with a response typically seen within two months. Because this was a review of past clinical records rather than a controlled trial, the result cannot show how much improvement was caused by tranexamic acid alone.
There is also limited direct evidence comparing oral treatment with topical TXA. Behrooz Heidary and colleagues ran a single-centre randomized trial in Yazd, Iran, involving 50 women. After 12 weeks, MASI scores fell in both groups: by about 59% with oral treatment and 51% with a 5% cream. The difference between groups was not statistically significant. This small study suggests a topical option may help, but it does not prove the two approaches are equally effective for everyone.
Recurrence After Stopping Is Common
In the Singapore study, 27.2% of those who improved later had a relapse. A 2023 review by Klara Gaćina and Anđela Krstanović Ćosić reports a median of seven months between stopping treatment and recurrence in that group. Other studies also describe relapse, although follow-up periods differ. These findings mean that fading during treatment does not guarantee lasting clearance once you stop.
Melasma is prone to recurrence, and studies often included sunscreen as part of treatment. Ongoing sun protection and a plan for managing pigmentation after a course of TXA are worth discussing with your clinician. They can also help you compare other melasma treatment options, including topical treatments, rather than treating oral medication as the only route.
Why Clotting And Health Screening Matters
Tranexamic acid is an antifibrinolytic medicine: it reduces bleeding by slowing the breakdown of fibrin, a protein involved in blood clots. That action is why a personal history of blood clots, a known clotting disorder, or a close family history of thrombosis needs careful discussion before use. In Lee and colleagues’ study, one person developed deep vein thrombosis and was later found to have familial protein S deficiency. A single case does not tell us the overall risk, but it shows why screening cannot be skipped.
Tell your clinician about your medical conditions, medicines, previous clotting or bleeding problems, and family history. Pregnancy, breastfeeding, use of oral contraceptives and major systemic illness were among the factors that led to exclusion from some melasma studies; your clinician can assess what applies to you. Study participants sometimes had laboratory tests, but those study procedures do not establish one universal screening panel. A clinician should decide whether tests are appropriate for your circumstances.
Reported side effects in melasma studies include stomach discomfort and menstrual changes. The studies are not large or long enough to prove that serious clotting events cannot occur or to give a precise risk estimate for every patient. Do not start, borrow or change a dose of tranexamic acid without medical supervision.
Off-Label Use And Regional Availability
The dose used in studies varies; 250 mg twice daily is common, but it is not an established, approved melasma regimen. A comparative study of 132 adults tested 250 mg once daily against 500 mg twice daily for 16 weeks. Only 88 completed it, and the authors noted limitations including short follow-up. It does not settle the safest or most effective dose for long-term use.
Approval depends on the condition being treated. In the United States, the FDA approves oral tranexamic acid for cyclic heavy menstrual bleeding, not melasma. An Indian expert consensus published in 2023 likewise stated that melasma use was not approved by the US FDA or India’s Drug Controller General. The US and India examples do not establish the rules or availability in the UK, EU or Australia; those details may differ by country and should be checked with a local prescriber or medicines regulator. In any region, a prescription for melasma is a clinician’s off-label decision, not a cosmetic supplement recommendation.
If you are considering treatment, ask what improvement would count as worthwhile, how long a course would last, how your clotting and health history affects the decision, and what the plan is if pigmentation returns. Seek medical advice before using TXA, especially if you have a history of clotting problems or are pregnant or breastfeeding.